Your browser doesn't support javascript.
loading
Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.
Dörner, Thomas; van Vollenhoven, Ronald F; Doria, Andrea; Jia, Bochao; Ross Terres, Jorge A; Silk, Maria E; de Bono, Stephanie; Fischer, Peter; Wallace, Daniel J.
Affiliation
  • Dörner T; Department Medicine/Rheumatology and Clinical Immunology, Charite - Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Chariteplatz, 01 10117, Berlin, Germany. thomas.doerner@charite.de.
  • van Vollenhoven RF; University Medical Center, Amsterdam, The Netherlands.
  • Doria A; University of Padova, Padova, Italy.
  • Jia B; Eli Lilly and Company, Indianapolis, IN, USA.
  • Ross Terres JA; Eli Lilly and Company, Indianapolis, IN, USA.
  • Silk ME; Eli Lilly and Company, Indianapolis, IN, USA.
  • de Bono S; Eli Lilly and Company, Indianapolis, IN, USA.
  • Fischer P; Eli Lilly and Company, Indianapolis, IN, USA.
  • Wallace DJ; Cedars-Sinai Medical Center and University of California at Los Angeles, Los Angeles, CA, USA.
Arthritis Res Ther ; 24(1): 112, 2022 05 16.
Article in En | MEDLINE | ID: mdl-35578304
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Lupus Erythematosus, Systemic Type of study: Clinical_trials Limits: Humans Language: En Journal: Arthritis Res Ther Journal subject: REUMATOLOGIA Year: 2022 Type: Article Affiliation country: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Lupus Erythematosus, Systemic Type of study: Clinical_trials Limits: Humans Language: En Journal: Arthritis Res Ther Journal subject: REUMATOLOGIA Year: 2022 Type: Article Affiliation country: Germany